comprehensive -WSS

comprehensive

author：hotspot 2025-10-01 04:33:03 - browse：249

President Biden's White House announced the first 10 medicines that will be up first in its new drug price negotiation program. Anna Moneymaker/Getty Images

WASHINGTON — Medicare on Tuesday announced it will negotiate prices for 10 drugs, including major blood thinners and diabetes medications, in the first round of its negotiation program created in Democrats’ drug pricing reform law.

The drugs include Bristol Myers Squibb’s blood thinner Eliquis, Boehringer Ingelheim and Eli Lilly’s diabetes drug Jardiance, Johnson & Johnson’s blood thinner Xarelto, Merck’s diabetes drug Januvia, AstraZeneca’s diabetes drug Farxiga, Novartis’ heart failure treatment Entresto, Amgen’s rheumatoid arthritis drug Enbrel, Johnson & Johnson and AbbVie’s blood cancer treatment Imbruvica, J&J’s anti-inflammatory medicine Stelara, and Novo Nordisk insulins that go by names including Fiasp and NovoLog.

The new prices will be announced on Sept. 1, 2024, and will go into effect on Jan. 1, 2026. The drugs were chosen from a list of 50 treatments that cost Medicare’s pharmacy drug benefit the most money. The selected medicines cost Medicare more than $50 billion and made up 20% of the Medicare program’s pharmacy drug costs over a one-year period, the Department of Health and Human Services said. (Read more here about the winners and losers of the selection.)

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

hotspot

WSS

Group behind ProMed defends move to subscription

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

Pfizer plans to depart BIO

H.R. 3 is the wrong path to lower drug costs

Personalized medicine goes far beyond genetics

Patients' immediate access to test results puts radiologists in a bind

knowledge

comprehensive

hotspot

Hepatitis C has a cure — but many Americans still lack access to it

Supreme Court wrestles with OxyContin maker's bankruptcy deal

Medical leaders decry Supreme Court decision on affirmative action

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

Heart attack and stroke risk calculators need revising

Study links childhood stress with decline in older age

Medicare proposal to cover medical devices draws a mixed reaction

When waiting feels immoral: Empathy in the emergency department

In Memoriam: Notable people who died in 2023

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

Wikipedia

Heart disease in astronauts blamed on cosmic radiation

It costs an awful lot of money to give away a kidney

Why sickle cell disease is getting the first CRISPR treatment

CMS should re

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

AI models in health care face new federal disclosure requirements

hotspot

Wikipedia

hotspot

knowledge